Resistin is a cysteine-rich peptide hormone that is secreted by adipocytes. The discovery of resistin goes back to 2001 and to the group of Lazar from the University of Pennsylvania. It was called “resistin” due to its observed insulin resistance in injected mice (
1). It is evident that resistin is an adipocyte-secreted hormone with critical roles in energy, lipids, and glucose homeostasis. However, its specific roles during fetal and neonatal periods remain poorly understood (
1-
4). Several studies have provided support for the concept where insulin resistance and obesity are associated with a decreased resistin expression, which is regulated by many factors such as thiazolidinediones, tumor necrosis factor alpha, insulin, and growth hormone (
5,
6). Some studies showed that umbilical cord resistin level had a positive association with maternal resistin level and it was associated with the gestational age and birth weight (
7,
8). Another study showed that adiponectins are involved in insulin resistance during gestation, however, Resistin seems to have a minor role (
9). Thus, some studies showed that the umbilical cord blood resistin was not correlated with the type of delivery, neonate’s gender, maternal age or body mass index (BMI), and neonatal birth weight (
8,
10). Yeung et al. revealed that newborn blood adipokines are associated with birth outcomes, especially preterm birth and small for gestational age neonate (SGA) (
11).
Due to conflicting data regarding the relationship between serum resistin and neonatal growth, the controversies between this association in term, and preterm neonates or appropriate for gestational age (AGA) and SGA ones, the present study focuses on the relevance between the resistin level in the umbilical cord serum and fetal birth weight in AGA and SGA versus term and preterm newborns.